Alexandre dos Santos Pyrrho

Alexandre dos Santos Pyrrho

Auto-generated profile, based on publicly available information

Alexandre dos Santos Pyrrho

Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2012 in Toxicology Research
Verified
Journal Article
Open access
PDF file
MMMalachy McCann
Malachy McCann
ASAndré L. S. Santos
André L. S. Santos
BSBianca A. da Silva
Bianca A. da Silva
MRMaria Teresa V. Romanos
Maria Teresa V. Romanos
APAlexandre S. Pyrrho
Alexandre S. Pyrrho
AKAndrew Kellett
Andrew Kellett
1,10-Phenanthroline (phen, 5), 1,10-phenanthroline-5,6-dione (phendione, 6), [Cu(phendione)3](ClO4)2·4H2O (12) and [Ag(phendione)2]ClO4 (13) are highly active, in vitro, against a range of normal and cancerous mammalian cells, fungal and insect cell lines, with the metal complexes offering a clear enhancement in activity. Cytoselectivity was not observed between the tumorigenic and non-tumorigenic mammalian lines. In in vivo tests, using Galleria mellonella and Swiss mice, all four compounds were well tolerated in comparison to the clinical agent, cisplatin. In addition, blood samples taken from the Swiss mice showed that the levels of the hepatic enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), remained unaffected. Immunocompromised nude mice showed a much lower tolerance to 13 and, subsequently, when these mice were implanted with Hep-G2 (hepatic) and HCT-8 (colon) human-derived tumors, there was no influence on tumor growth.

1 May 2013 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
ACAna Cristina Trindade Cursino
Ana Cristina Trindade Cursino
FLFábio da Silva Lisboa
Fábio da Silva Lisboa
APAlexandre dos Santos Pyrrho
Alexandre dos Santos Pyrrho
VSValeria Pereira de Sousa
Valeria Pereira de Sousa
FWFernando Wypych
Fernando Wypych

16 December 2008 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
EMElizabeth S. Magalhaes
Elizabeth S. Magalhaes
CPClaudia N. Paiva
Claudia N. Paiva
HSHeitor S De Souza
Heitor S De Souza
APAlexandre S. Pyrrho
Alexandre S. Pyrrho
DMDiego Mourao-Sá
Diego Mourao-Sá
MBMarcelo T. Bozza
Marcelo T. Bozza

29 July 2009 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
CPCláudia N. Paiva
Cláudia N. Paiva
RFRodrigo T. Figueiredo
Rodrigo T. Figueiredo
KKKarina Kroll-Palhares
Karina Kroll-Palhares
ASAndrea A Silva
Andrea A Silva
JSJaline C. Silvério
Jaline C. Silvério
MBMarcelo T. Bozza
Marcelo T. Bozza
CCL2/MCP-1 has emerged recently as a critical factor in infectious and autoimmune myocarditis. In fact, this chemokine is produced in great amounts in hearts from Trypanosoma cruzi-infected mice and is known to enhance parasite uptake and destruction by macrophages. Herein, we studied the involvement of CCL2 in tissue inflammation and resistance to T. cruzi. Infected CCL2−/− mice developed higher parasitemias and died earlier than WT mice. Close to their death, T. cruzi-infected CCL2−/− presented greater amounts of TNF, IFN-γ, and IL-10 in plasma than WTs and clinical signs of systemic inflammatory response. Amastigote nests were more frequent in hearts and livers from infected CCL2−/− tissues than in WTs, and reduced numbers of leukocytes infiltrated their tissues. Leukocytes formed diffuse but not focal infiltrates in hearts from infected CCL2−/− mice, and perivascular cuffs could still be found in their livers. Infected CCL2−/− mice had smaller percentages of activated CD11b (Mac-1)+CD107b (Mac-3)+ macrophages and CD8+CD69hi cells among heart and liver infiltrates than WTs (flow cytometry), indicating that CCL2 controls subset migration/activation. CCL2 accumulated among focal heart infiltrates, suggesting that this chemokine is involved in retention of mononuclear cells in particular spots. Peritoneal macrophages from CCL2−/− mice displayed decreased trypanocidal activity. Our results demonstrate that CCL2 contributes to reduce parasite growth and indicate that it does so by controlling the distribution, cellular composition, and state of activation of inflammatory infiltrates in acute T. cruzi infection.

1 April 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
HMHílton Antônio Mata-Santos
Hílton Antônio Mata-Santos
FDFabianno Ferreira Dutra
Fabianno Ferreira Dutra
CRCarolina Carneiro Rocha
Carolina Carneiro Rocha
FLFabiana Gonçalves Lino
Fabiana Gonçalves Lino
FXFabiola Ramos Xavier
Fabiola Ramos Xavier
APAlexandre dos Santos Pyrrho
Alexandre dos Santos Pyrrho
In chronic schistosomiasis, hepatic fibrosis is linked to the portal hypertension that causes morbidity inSchistosoma mansoniinfection. Silymarin (SIL) is a hepatoprotective and antioxidant medicament largely prescribed against liver diseases that has previously been shown to prevent fibrosis during acute murine schistosomiasis. Here we employed silymarin to try to reverse established hepatic fibrosis in chronic schistosomiasis. Silymarin or vehicle was administered to BALB/c mice every 48 h, starting on the 40th (80 days of treatment), 70th (50 days), or 110th (10 days) day postinfection (dpi). All mice were sacrificed and analyzed at 120 dpi. Treatment with silymarin reduced liver weight and granuloma sizes, reduced the increase in alanine aminotransferase and aspartate aminotransferase levels, and reduced the established hepatic fibrosis (assessed by hydroxyproline contents and picrosirius staining). Treatment with silymarin also reduced the levels of interleukin-13 (IL-13) in serum and increased the gamma interferon (IFN-γ)/IL-13 ratio. There was a linear correlation between IL-13 levels in serum and hydroxyproline hepatic content in both infected untreated and SIL-treated mice, with decreased IL-13 levels corresponding to decreased hydroxyproline hepatic contents. Treatment with either SIL or N-acetylcysteine reduced both proliferation of fibroblast cell lines and basal/IL-13-induced production of collagen I, indicating that besides inhibiting IL-13 production during infection, SIL antioxidant properties most likely contribute to inhibition of collagen production downstream of IL-13. These results show that silymarin interferes with fibrogenic cytokines, reduces established fibrosis, and inhibits downstream effects of IL-13 on fibrogenesis, indicating the drug as a safe and cheap treatment to liver fibrotic disease in schistosomiasis.

12 September 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AVAmanda R. R. Vicentino
Amanda R. R. Vicentino
VCVitor C. Carneiro
Vitor C. Carneiro
DADiego Allonso
Diego Allonso
RGRafael de Freitas Guilherme
Rafael de Freitas Guilherme
CBClaudia Farias Benjamim
Claudia Farias Benjamim
MFMarcelo Rosado Fantappié
Marcelo Rosado Fantappié
In chronic schistosomiasis, liver fibrosis is linked to portal hypertension, which is a condition associated with high mortality and morbidity. High mobility group box 1 (HMGB1) was originally described as a nuclear protein that functions as a structural co-factor in transcriptional regulation. However, HMGB1 can also be secreted into the extracellular milieu under appropriate signal stimulation. Extracellular HMGB1 acts as a multifunctional cytokine that contributes to infection, injury, inflammation, and immune responses by binding to specific cell-surface receptors. HMGB1 is involved in fibrotic diseases. From a clinical perspective, HMGB1 inhibition may represent a promising therapeutic approach for treating tissue fibrosis. In this study, we demonstrate elevated levels of HMGB1 in the sera in experimental mice or in patients with schistosomiasis. Using immunohistochemistry, we demonstrated that HMGB1 trafficking in the hepatocytes of mice suffering from acute schistosomiasis was inhibited by Glycyrrhizin, a well-known HMGB1 direct inhibitor, as well as by DIC, a novel and potential anti-HMGB1 compound. HMGB1 inhibition led to significant downregulation of IL-6, IL4, IL-5, IL-13, IL-17A, which are involved in the exacerbation of the immune response and liver fibrogenesis. Importantly, infected mice that were treated with DIC or GZR to inhibit HMGB1 pro-inflammatory activity showed a significant increase in survival and a reduction of over 50% in the area of liver fibrosis. Taken together, our findings indicate that HMGB1 is a key mediator of schistosomotic granuloma formation and liver fibrosis and may represent an outstanding target for the treatment of schistosomiasis.